Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD

Author:

Donohue James F.ORCID,Burgoyne Douglas S.,Ward Jonathan K.,Allan RichardORCID,Koltun ArkadyORCID,Cooper AndrewORCID

Funder

Mylan Inc

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine,Respiratory Care

Reference22 articles.

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (2020). Accessed 12 June 2020.

2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.1wms.pdf (2020). Accessed 12 June 2020.

3. Allan R, Haughie S, Ahrens R, et al. A dose-response study examining the use of methacholine challenge to demonstrate local therapeutic equivalence of the salmeterol component of generic inhaled fluticasone propionate/salmeterol combination products. J Aerosol Med Pulm Drug Deliv. 2019;32:352–63.

4. Mylan announces FDA approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), first generic of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder. Hertfordshire, England and Pittsburgh, PA. 31 Jan 2019.

5. Advair Diskus prices, coupons and patient assistance programs. Updated November 2, 2020. https://www.drugs.com/price-guide/advair-diskus. Accessed 11 Nov 2020.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Pulmonary;Practical Pharmaceutics;2023

2. Patient Perceptions of Switching to a Generic Dry Powder Inhaler – Increased Understanding Through Journey Mapping;International Journal of Chronic Obstructive Pulmonary Disease;2022-08

3. Half a Century of Technological Advances in Pulmonary Drug Delivery: A Personal Perspective;Frontiers in Drug Delivery;2022-04-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3